Nektar Therapeutics (NKTR)

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

 

COMPANY ADDRESS
455 Mission Bay Boulevard South
San Francisco, California 94158
United States

COMPANY PHONE
415-482-5300

COMPANY WEBSITE



Get BioInvest's perspective on Nektar Therapeutic's CEO


Latest Company News

Nektar Therapeutics (NKTR) Earning Positive Press Coverage, Accern Reports The Cerbat Gem - 1 hour ago Nektar Therapeutics logo Press coverage about Nektar Therapeutics (NASDAQ:NKTR) has trended positive this week, according to Accern Sentiment. Thoughts on the Momentum: Nektar Therapeutics (NKTR), Realty Income ... - Post Analyst Nektar Therapeutics (NKTR) Upgraded to “Buy” by BidaskClub - Markets Daily [...]
Tue, Jun 27, 2017 9:11:00 PM, Continue reading at the source
Nektar Therapeutics (NasdaqGS:NKTR) Valuation in Focus Concord Register - 9 hours ago Nektar Therapeutics (NasdaqGS:NKTR) has an ERP5 rank of 15028. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. [...]
Tue, Jun 27, 2017 1:18:00 PM, Continue reading at the source
Nektar Therapeutics (NasdaqGS:NKTR): Is The Stock Undervalued? Concord Register - 9 hours ago Nektar Therapeutics (NasdaqGS:NKTR) has an ERP5 rank of 15028. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. [...]
Tue, Jun 27, 2017 1:18:00 PM, Continue reading at the source
Investors Are Circling Nektar Therapeutics (NasdaqGS:NKTR), What Do the ... Stock Talker - 12 hours ago The Shareholder Yield of Nektar Therapeutics (NasdaqGS:NKTR) is -13.16%. The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and ... [...]
Tue, Jun 27, 2017 9:33:00 AM, Continue reading at the source
Nektar Therapeutics (NasdaqGS:NKTR): A look at Yield & Technicals Trion Journal - Jun 26, 2017 The EBITDA Yield for Nektar Therapeutics (NasdaqGS:NKTR) is -4.55%. The EBITDA Yield is a great way to determine a company's profitability. [...]
Mon, Jun 26, 2017 10:18:00 PM, Continue reading at the source
Active Runner in Focus: Nektar Therapeutics (NKTR) Evergreen Caller - Jun 26, 2017 Needle moving action has been spotted in Nektar Therapeutics (NKTR) as shares are moving today on volatility -0.80% or -0.16 from the open. [...]
Mon, Jun 26, 2017 3:24:00 PM, Continue reading at the source
Nektar Therapeutics Risk Points versus Health Care CML News - Jun 17, 2017 This is a scatter plot analysis of the critical risk points from the option market for Nektar Therapeutics (NASDAQ:NKTR) compared to its own past and the Health Care ETF. Analysts Set Nektar Therapeutics (NKTR) PT at $26.29 - The Cerbat Gem The Nektar Therapeutics (NKTR) Receives Daily News Sentiment Score of 0.31 - BangaloreWeekly [...]
Sat, Jun 17, 2017 10:52:00 PM, Continue reading at the source
Nektar Therapeutics: A Sweet Or Sour Investment? Seeking Alpha - Jun 14, 2017 After a decade plus of failed investment in the inhaled insulin, Exubera, Pfizer Inc. (NYSE:PFE) cut the losses via terminating its partnership with Nektar Therapeutics (NASDAQ:NKTR) on Oct. 18, 2007. Next year, Nektar gave up the hope for inhaled ... Nektar Therapeutics (NKTR) SVP Sells $33254.55 in Stock - The Cerbat Gem The -$0.34 EPS Expected for Nektar Therapeutics (NKTR) This Quarter - BangaloreWeekly [...]
Wed, Jun 14, 2017 3:22:00 PM, Continue reading at the source
Nektar Therapeutics (NKTR) Plunges 5.21% on June 12 Equities.com - Jun 12, 2017 Nektar Therapeutics (NKTR) had a rough trading day for Monday June 12 as shares tumbled 5.21%, or a loss of $-0.99 per share, to close at $18.03. [...]
Mon, Jun 12, 2017 9:30:00 PM, Continue reading at the source
Checking the Overall Picture for Nektar Therapeutics (NKTR) StockNewsJournal - Jun 8, 2017 Nektar Therapeutics (NKTR) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $18.85, down from yesterday's close by -4.22%. Nektar Therapeutics | $NKTR Stock | Shares Fall as Company Announces New ... - TickerTV News (press release) The Technical Chart For Nektar Therapeutics (NKTR) Is Speaking Volumes - NY Stock News [...]
Thu, Jun 08, 2017 4:30:00 PM, Continue reading at the source